TENAX THERAPEUTICS, INC.
Reads like this one publish minutes after the filing lands on EDGAR. Get them as JSON over the API or inside your AI agent over MCP.
ADAR1 Capital Management, LLC purchased 770,333 indirectly-held shares of TENAX THERAPEUTICS, INC. (TENX) at an average of $1.79 ($1.79–$1.80, $1.38M total) across 3 trades over 2026-08-31 to 2026-09-02. Filed jointly with Schneeberger Daniel (10% owner).
Analysts upgraded Deere (DE) to Outperform with a $800 target, citing strong North American demand. Abercrombie & Fitch (ANF) was upgraded to Buy with a $162 target after Q2 earnings beat. Agco (AGCO) upgraded to Outperform with a $150 target, expecting 2027 volume recovery. Kaiser Aluminum (KALU) upgraded to Buy with a $184 target. Stag Industrial (STAG) upgraded to Outperform. PG&E (PCG) downgraded by Wells Fargo and BMO. Mizuho downgraded PG&E, Sempra Energy (SRE), and Edison International (E
Analysts downgraded Sempra (SRE) from Outperform to Neutral, cutting its price target from $104 to $84. PG&E (PCG) was downgraded from Outperform to Market Perform with a target reduced from $28 to $21. Edison International (EIX) was also downgraded to Neutral with a target lowered from $86 to $70. MINISO Group (MNSO) was downgraded to Hold with a $10.8 target. Tenax Therapeutics (TENX) was downgraded to Neutral.
Over the past 7 days, alphai's AI scored 5 news stories mentioning TENX (TENAX THERAPEUTICS, INC.). Coverage has skewed bullish: 3 bullish, 0 neutral, and 2 bearish.
Recent TENX coverage spans financial news, insider activity and technology.
In the last 30 days, TENX insiders filed 6 SEC Form 4 transactions — 6 purchases ($3.2M) and no sales. The most active reporter was ADAR1 Capital Management, LLC with 6 filings.
Insider purchase signals confidence but the transaction size is modest relative to market cap.
Downgrade due to trial uncertainty.
A downgrade can reduce incremental demand from analysts and investors, particularly for small-cap biotech sentiment.
Positive Phase 3 data showing treatment benefit and NT‑proBNP reduction were disclosed for the first time.
Positive trial results may boost Tenax's valuation and accelerate regulatory discussions.
alphai scores every news story that mentions TENX with an AI model for sentiment and relevance, and aggregates insider trades from TENAX THERAPEUTICS, INC.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
ADAR1 Capital Management, LLC purchased 770,333 indirectly-held shares of TENAX THERAPEUTICS, INC. (TENX) at an average of $1.79 ($1.79–$1.80, $1.38M total) across 3 trades over 2026-08-31 to 2026-09-02. Filed jointly with Schneeberger Daniel (10% owner).
1 min readAnalysts upgraded Deere (DE) to Outperform with a $800 target, citing strong North American demand. Abercrombie & Fitch (ANF) was upgraded to Buy with a $162 target after Q2 earnings beat. Agco (AGCO) upgraded to Outperform with a $150 target, expecting 2027 volume recovery. Kaiser Aluminum (KALU) upgraded to Buy with a $184 target. Stag Industrial (STAG) upgraded to Outperform. PG&E (PCG) downgraded by Wells Fargo and BMO. Mizuho downgraded PG&E, Sempra Energy (SRE), and Edison International (E
2 min readAnalysts downgraded Sempra (SRE) from Outperform to Neutral, cutting its price target from $104 to $84. PG&E (PCG) was downgraded from Outperform to Market Perform with a target reduced from $28 to $21. Edison International (EIX) was also downgraded to Neutral with a target lowered from $86 to $70. MINISO Group (MNSO) was downgraded to Hold with a $10.8 target. Tenax Therapeutics (TENX) was downgraded to Neutral.
4 min readTenax Therapeutics (TENX) stock rose 3.8% in pre-market trading after presenting additional Phase 3 trial data at the European Society of Cardiology Congress. The data showed favorable treatment effects for TNX-103 in patients with severe pulmonary hypertension due to heart failure. Several Wall Street firms initiated coverage with Buy ratings and price targets of $35-$40. The company has $118 million in cash, providing a runway through Q2 2028.
2 min readTenax Therapeutics (TENX) presented additional Phase 3 LEVEL trial data showing TNX-103 improved 6MWD, NT-proBNP, and RVSP in PH-HFpEF patients with lower baseline walk distance. The company plans to enrich the LEVEL-2 population based on these results. TNX-103 showed a 26.3m 6MWD improvement, 47% NT-proBNP reduction, and 4.9 mmHg RVSP reduction vs. placebo in this subgroup.
3 min readTenax Therapeutics (TENX) rose 27.8% premarket despite a Phase 3 trial setback, planning to discuss revised development plans with the FDA. TherapeuticsMD (TXMD) reported Q2 revenue decline but expects a milestone payment. Kura Oncology (KURA) gained 10.38% on strong Komzifti adoption. Anavex Life Sciences (AVXL) returned to profit in Q3 2026, advancing blarcamesine. Immatics (IMTX) rose 6.78% after a $150M offering. RenovoRx (RNXT) gained 16.40% on positive pancreatic cancer data.
3 min readSeveral biotech stocks are trading higher in premarket, including Autonomix Medical (AMIX) up 29% at $6.92, Picard Medical (PMI) up 12% at $5.85, and others. The gains indicate early momentum and potential volatility for the trading day, according to the market activity.
1 min readInsider trading activity reported for US public companies includes significant purchases and sales. ADAR1 Capital bought 1.03M Tenax Therapeutics (TENX) shares for $1.81M. Kenneth Courtis acquired 15K Alpha Metallurgical (AMR) shares for $3.16M. Rex Geveden bought 5K TTM Technologies (TTMI) shares for $524.5K. Ashley McEvoy, CEO of Insulet (PODD), purchased 1.1K shares for $162.2K. Notable sales include James Wirth selling IHT shares for $1.82B, Alexander Karp selling 492K Palantir (PLTR) shares
3 min readADAR1 Capital Management, LLC purchased 1,025,867 indirectly-held shares of TENAX THERAPEUTICS, INC. (TENX) at an average of $1.77 ($1.75–$1.78, $1.81M total) across 3 trades over 2026-08-20 to 2026-08-24. Filed jointly with Schneeberger Daniel (10% owner).
1 min readTenax Therapeutics (TENX) shares dropped 84-85% after its Phase 3 LEVEL trial for TNX-103 failed primary and key secondary endpoints. The company is pre-revenue, and TNX-103 was its lead program. Levi & Korsinsky is investigating potential securities law violations on behalf of affected investors.
2 min read
